Progress in transplantation

Therapeutic Drug Monitoring

Volumn 32, Issue 3, 2010, Pages 246-249

  Levy, Gary A ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Immunosuppression; Rejection; Tolerance; Transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; LIVER CELL CARCINOMA; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; TRANSPLANTATION TOLERANCE; WAITING LISTS;

EID: 77952954186     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181dca981     Document Type: Conference Paper

References (40)

1. Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. Transplantation. 1988;45:673-676.
2. Halloran PF, Broski AP, Batiuk TD, et al. The molecular immunology of acute rejection: an overview. Transpl Immunol. 1993;1:3-27.
3. Hoffman B, Sollinger H, Kalayoglu M, Belzer FO. Use of UW solution for kidney transplantation. Transplantation. 1988;46:338-339.
4. Lechler RI, Sykes M, Thomson AW, et al. Organ transplantation-how much of the promise has been realized? Nat Med. 2005;11:605-613.
5. Mengel M, Chapman JR, Cosio FG, et al. Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. Am J Transplant. 2007;7:512-517.
6. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med. 2003;349:125-138. (Pubitemid 36818782)
7. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol. 2000;20:108-125.
8. Katz SM, Hong JC, Kahan BD. New immunosuppressive agents. Transplant Proc. 2000;32:620-621.
9. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6: 1111-1131.
10. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant. 2002;2:898-903.
11. Shah SA, Grant DR, Greig PD, et al. Analysis and outcomes of right lobe hepatectomy in 101 consecutive living donors. Am J Transplant. 2005;5: 2764-2769.
12. Shah SA, Levy GA, Adcock LD, Gallagher G, Grant DR. Adult-to-adult living donor liver transplantation. Can J Gastroenterol. 2006;20:339-343.
13. Cattral MS, Lilly LB, Levy GA. Immunosuppression in liver transplantation. Semin Liver Dis. 2000;20:523-531.
14. Davies NM, Grinyo J, Heading R, et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant. 2007;22:2440-2448.
15. Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007;7:560-570.
16. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715-2729.
17. Levy GA. Long-term immunosuppression and drug interactions. Liver Transpl. 2001;7:S53-S59.
18. Meier-Kriesche HU, Hricik DE. Are we ready to give up on calcineurin inhibitors? Am J Transplant. 2006;6:445-446.
19. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
20. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341: 1725-1730.
21. Kahan BD. Cyclosporine. N Engl J Med. 1989;321:1725-1738.
22. Busuttil RW, Lake JR. Role of tacrolimus in the evolution of liver transplantation. Transplantation. 2004;77:S44-S51.
23. Roberts JP, Lake JR, Hebert M, et al. Reversal of chronic rejection after treatment failure with FK506 and RS61443. Transplantation. 1993;56: 1021-1023.
24. Firpi RJ, Soldevila-Pico C, Morelli GG, et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci. 2010;55:196-203.
25. Selzner N, Girgrah N, Lilly L, et al. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl. 2008;14:1778-1786.
26. Selzner N, Renner EL, Selzmer M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88:1214-1221.
27. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. 2004;10:1301-1311.
28. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with Belatacept in renal transplantation. N Engl J Med. 2005;353:770-781.
29. Bluestone JA. CTLA-4Ig is finally making it: a personal perspective. Am J Transplant. 2005;5:423-424.
30. Keown PA. New concepts in cyclosporine monitoring. Curr Opin Nephrol Hypertens. 2002;11:619-626.
31. Levy GA. Neoral C(2) in liver transplant recipients. Transplant Proc. 2001;33:3089-3091.
32. Levy GA. C2 monitoring strategy for optimising cyclosporin immuno-suppression from the Neoral formulation. BioDrugs. 2001;15:279-290.
33. Mishra J, Ma Q, Kelly C, et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol. 2006;21: 856-863.
34. Trachtman H, Christen E, Cnaan A, et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol. 2006;21:989-994.
35. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663-668.
36. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest. 2008;118:2845-2857.
37. Naesens M, Butte AJ, Sarwal MM. C3 polymorphisms and outcomes of renal allografts. N Engl J Med. 2009;360:2478-2479.
38. Sykes M. Immune tolerance: mechanisms and application in clinical transplantation. J Intern Med. 2007;262:288-310.
39. Chen W, Bluestone JA, Herold KC. Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol. 2005;24:287-305.
40. Fehr T, Sykes M. Tolerance induction in clinical transplantation. Transpl Immunol. 2004;13:117-130.